Nov 24 (Reuters) - Median Technologies SA ALMDT.PA :
* IBIOPSY®: PROMISING RESULTS ON A PRELIMINARY STUDY TO
IDENTIFY
THE SEVERITY OF THE DISEASE IN PATIENTS WITH NON-ALCOHOLIC
STEATOHEPATITIS (NASH)
* RESULTS SHOW THAT IBIOPSY® NON-INVASIVE FIBROSIS BIOMARKER
FOR
NASH COULD ALLOW FOR DISCRIMINATION BETWEEN EARLY AND ADVANCED
FIBROSIS BASED ON STANDARD IMAGING MODALITIES
* RESULTS NEED TO BE CONFIRMED ON INDEPENDENT PATIENT
COHORTS
Source text for Eikon: ID:nBw9JBzlla
Further company coverage: ALMDT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))